Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells

Peiying Yu, Weixing Han, Van Anthony M. Villar, Yu Yang, Quansheng Lu, Hewang Lee, Fengmin Li, Mark T. Quinn, John J. Gildea, Robin A. Felder, Pedro A. Jose

A R T I C L E   I N F O

Article history:
Received 26 December 2013
Received in revised form 28 January 2014
Accepted 30 January 2014
Available online 22 February 2014

Keywords:
NOX5
ROS
Oxidative stress
Dopamine receptor

A B S T R A C T

NADPH oxidases are the major sources of reactive oxygen species in cardiovascular, neural, and kidney cells. The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents. Because Nox isoforms in renal proximal tubules (RPTs) are involved in the pathogenesis of hypertension, we tested the hypothesis that NOX5 is differentially expressed in RPT cells from normotensive (NT) and hypertensive subjects (HT). We found that NOX5 mRNA, total NOX5 protein, and apical membrane NOX5 protein were 4.2 \( \pm \) 0.7-fold, 5.2 \( \pm \) 0.7-fold, and 2.8 \( \pm \) 0.5-fold greater in HT than NT. Basal total NADPH oxidase activity was 4.5 \( \pm \) 0.2-fold and basal NOX5 activity in NOX5 immunoprecipitates was 6.2 \( \pm \) 0.2-fold greater in HT than NT \((P < 0.001, n = 6–14/group). Ionomycin increased total NOX and NOX5 activities in RPT cells from HT \((P < 0.01, n = 4, ANOVA), effects that were abrogated by pre-treatment of the RPT cells with diphenyleneiodonium or superoxide dismutase. Silencing NOX5 using NOX5-siRNA decreased NADPH oxidase activity \((-45.1 \pm 3.2\% \text{ vs. mock-siRNA, } n = 6–8) \text{ in HT. D1-like receptor stimulation decreased NADPH oxidase activity to a greater extent in NT} \((-32.5 \pm 1.8\%) \text{ than HT} \((-14.8 \pm 1.8). \text{ In contrast to the marked increase in expression and activity of NOX5 in HT, NOX1 mRNA and protein were minimally increased in HT, relative to NT; total NOX2 and NOX4 proteins were not different between HT and NT, while the increase in apical RPT cell membrane NOX1, NOX2, and NOX4 proteins in HT, relative to NT, was much less than those observed with NOX5. Thus, we demonstrate, for the first time, that NOX5 is expressed in human RPT cells and to greater extent than the other Nox isoforms in HT than NT. We suggest that the increased expression of NOX5, which may be responsible for the increased oxidative stress in RPT cells in human essential hypertension, is caused, in part, by a defective renal dopaminergic system.

© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Introduction

The reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidases have been studied extensively in phagocytic and non-phagocytic cells, including those from cardiovascular, neural, pulmonary, and renal tissues [1–3]. The NADPH oxidase family, which has seven members, is classified into three groups: group 1, comprised of NOX1, NOX2, NOX3, NOX4; group 2, comprised of NOX5; and group 3, comprised of DOU1 and DOU2 [1]. NADPH oxidase-dependent enzymes are the major sources of reactive oxygen species (ROS) in non-phagocytic cells, including cardiovascular, neural, and renal cells [2,4–9]. ROS are important in intracellular signaling. However, excessive ROS production can lead to cell injury and death [2,9,10]. Indeed, oxidative stress is thought to be important in the pathogenesis of many diseases, such as cardiovascular and renal diseases and hypertension [2,4,5,9–11].

NOX1, NOX2, and NOX4 are predominantly expressed in cardiovascular and renal tissues in humans and rodents [2,4–8]. The NOX5 gene, which is present in humans but not rodents [12,13]
was initially reported to be expressed in human testis, spleen, and lymph node [14]. More recently, NOX5 has been reported in human vascular endothelial and smooth muscle cells [9,15–17]. Five splice variants of human NOX5, namely NOX5α, NOX5β, NOX5γ, NOX5δ, and short NOX5, have been identified [14,15]. NOX5 differs from the other NADPH oxidase isoforms in that it contains an N-terminal calmodulin-like domain with four binding sites for Ca\(^{2+}\) (EF hands) and does not require p22\(^{phox}\) or other subunits for its activation [1,3]. NOX5 can be activated by thrombin, platelet-derived growth factor, angiotensin II, endothelin 1, and protein kinase C [15]. NOX5 can also be directly regulated by intracellular Ca\(^{2+}\), the binding of which induces a conformational change, leading to enhanced ROS generation [18–23].

Dopamine is an important regulator of sodium balance and blood pressure through an independent peripheral dopaminergic system [11,24,25]. Knockout of any of the dopamine receptor subtypes (D\(_{1}\)R, D\(_{2}\)R, D\(_{3}\)R, D\(_{4}\)R, and D\(_{5}\)R) results in hypertension, the pathogenesis of which is receptor subtype-specific [24]. D\(_{1}\)-like receptor (comprised of D\(_{1}\)R and D\(_{5}\)R) regulation of renal proximal tubule (RPT) sodium transport is defective in genetically hypertensive rats and patients with essential hypertension [11,24–32]. More specifically, D\(_{1}\)R function is impaired in RPT cells from humans with essential hypertension [33]. Both decreased dopamine receptor function and increased ROS production contribute to the pathogenesis of essential hypertension [2,11,24,25]. D\(_{1}\)-like receptors inhibit oxidative stress in vascular smooth muscle and RPT cells [11,28–31]. However, oxidative stress can also cause dysfunction of D\(_{1}\)R in rat RPT cells [32] and ROS production is increased in RPT cells from spontaneously hypertensive rats (SHRs) [34]. NADPH oxidase activity and protein levels of Nox2 and Nox4 are greater in kidneys and cerebral arteries of SHRs than those from their normotensive controls (Sprague-Dawley and Wistar-Kyoto [WKY]) rats [29,31]. Nox2 and Nox4 are greater in kidneys and cerebral arteries of SHRs [34]. NADPH oxidase activity and protein levels of SHRs were grown in culture [33]. These cells have been characterized for D1-like receptor expression and function (i.e., response to dopamine and dopamine receptor agonists and antagonists) [33,36]. The human RPT cells were maintained in phenol-free Dulbecco’s modified Eagle’s medium/F12 medium supplemented with 10% fetal bovine serum (FBS), epidermal growth factor (10 ng/ml), ITS\(^{TM}\) premix (insulin, transferrin, and selenium), hydrocortisone (36 ng/ml), triiodothyronine (4 μg/ml), and prirnicon (500 μg/ml) at 37 °C in humidified 5% CO\(_2/95%\) air [31,33,36].

Measurement of NOX5 activity in NOX5-immunoprecipitates

Because there is no specific test for NOX5 activity, we first isolated NOX5 from the other NADPH oxidase isoforms by immunoprecipitation, as described under “Materials and Methods”, Supplementary information. The immunoprecipitates (IPs) were washed twice with ice-cold PBS and then finally washed once with assay buffer. NOX5 assay buffer was reconstituted as described [9,19,23]. NOX5 activity was measured in duplicate, by incubating the NOX5 immunoprecipitates with assay buffer (200 μl) containing 1 × PBS buffer, pH 7.4, (mmol/L) 100 KCl, 2 MgCl\(_{2}\), and 1 EGTA, 100 μM FAD (Sigma-Aldrich), in the presence of 1.0 mmol/L CaCl\(_{2}\) and 50 μmol/L lucigenin. The reaction was allowed to proceed for 20 min at 37 °C in a water bath. The supernatants, in duplicate, were immediately transferred into a 96-well microplate and read on a luminometer (MicroWin 2000) at 25 °C following the injection (20 μl) of NADPH (200 μmol/L, final concentration) and monitored for 30 min. Normal rabbit IgG IPs served as negative controls. NOX5 activity was expressed as relative luminescence units (RLU) and converted to % change of NT as described previously [8,29,31].

Measurement of extracellular ROS production

Extracellular ROS production was measured in triplicate by the superoxide dismutase (SOD)-inhibitable reduction of cytochrome c (absorbance at 550 nm). Cells (5 × 10\(^6\) cells/well) cultured on 12-well plates were incubated in 0.5 ml phenol-free DMEM/F12 medium containing reduced cytochrome c (200 μmol/L) with or without SOD (200 μmol/L) for 15 min at 37 °C. The incubation was continued for another 30 min in the presence of vehicle or the D\(_{1}\)-like receptor agonist, fenoldopam (1 μmol/L), and the absorbance of reduced cytochrome c was measured at 550 nm optical density (OD), using a Victor spectrophotometer (PerkinElmer Life, Shelton, CT). SOD-inhibitable reduction of cytochrome c was calculated by the formula \( \text{nmol} = 159 \times (\text{OD} - \text{SOD} - \text{OD} + \text{SOD}) \) [37,38]. The results were expressed as nmol/5 × 10\(^6\) cells. To compare vehicle and drug treatment groups, the percentage of the absolute value of each drug treatment relative to the absolute mean of the vehicle-treated controls was calculated.
**Measurement of ROS production in live RPT cells by a fluorogenic probe**

Cells were initially grown on coverslips in DMEM/F12 complete medium. The medium was then changed to phenol-free DMEM/F12 medium containing 1% dialyzed FBS and the fluorogenic probe CellROS Deep Red reagent (5 μmol/L, final concentration) and incubated for 30 min at 37 °C. The cells were washed with PBS buffer three times, fixed with 4% paraformaldehyde in PBS buffer for 10 min, and mounted on coverslips using ProLong® Gold reagent. ROS fluorescence images were obtained using laser confocal scanning microscopy (Zeiss LSM 510) at excitation/emission wavelengths of 644/655 nm at 630x magnification. Using ZEN 2012 software NOX5 was colored green, ROS was colored red, and the merged image was yellow. In some cases 5-(and-6)-carboxy-2',7'-dichlorofluorescein diacetate (carboxy-DCFDA) was also used to measure ROS production (“Materials and Methods”, Supplementary information).

**Real-time quantitative PCR**

Total RNA was extracted from RPT cells with the RNeasy Mini Kit (Qiagen Inc., Valencia, CA) and reverse transcription (RT) was performed using M-MLV reverse transcriptase (Invitrogen). Two micro liters of the RT product was used for real-time PCR (SYBR Green qPCR Supermix UDG Kit, Invitrogen): 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 63 °C for 60 s. The human NOX5 primers were 5'-AACCTCTGG-GGACTGGCTGCT-3' (sense, nt #1251-71), and 5'-GAGGAGATGAGT-GACCTTGGA-3' (antisense, nt #1376-86). Human GAPDH primers were 5'-CTCTGGAGTCTACTGGCGTCTT-3' (sense), and 5'-CAGCTTCTCAGTGCCATGTGG-3' (antisense). Expression of the target gene was normalized against the expression of GAPDH (ABI Prism 7700 sequence detector system, Applied Biosystems, SDS (Ver. 1.91, Foster City, CA).

**Statistical analysis**

Numerical data were expressed as mean ± standard error of the mean (SEM). Significant difference between two groups was determined by the Student’s t-test. Significant differences among groups (>2) were determined by one-way factorial ANOVA followed by the Newman–Keuls test. P < 0.05 was considered significant.

**Results**

**Expression of NOX5 mRNA**

Previous studies have shown that mRNA and protein levels of NOx isoforms (Nos2, and Nos4) are greater in RPT cells from SHRs than WKY rats [31,39,40]; Nos1, Nos2, and Nos4 expressions are also increased in vascular smooth muscles of SHRs [4]. In the current report, we determined which NADPH oxidase isoform contributed to the enhanced NADPH oxidase activity in RPT cells from HT, relative to NT. In contrast to the studies in rats, we found that in human RPT cells, NOX2 and NOX4 mRNAs were similar in NT and NT. In agreement with the studies in vascular smooth muscle cells of SHRs [4], NOX1 mRNA was greater in HT than NT (Supplementary Fig. S1). The mRNA expression of NOX5, which is found in humans but not rodents, was also greater in HT (3.5 ± 0.1 fold) than NT (1.0 ± 0.2) (Fig. 1A). The increased basal NOX5 mRNA in HT relative to NT was verified by real-time qPCR: NOX5 mRNA was 4.2 ± 0.7-fold greater in HT than NT (P < 0.001, vs. NT, n=4, t-test) (Fig. 1B).

**Fig. 1.** Expression of NOX5 mRNA in human RPT cells. (A). RT-PCR analysis of human NOX5 mRNA in RPT cells from normotensive (NT) and hypertensive subjects (HT). The results were normalized with 36B4 mRNA, converted to % of NT, and shown as mean ± SEM. *P < 0.01 vs. NT, n=4, t-test. Two of four experiments are shown above the bar graphs. (B). Real-time quantitative PCR analysis of human NOX5 mRNA in human RPT cells. Reverse transcription (RT) utilized M-MLV reverse transcriptase and real-time quantitative PCR used the SYBR Green qPCR Supermix system. Results were normalized with GAPDH mRNA, converted to % of NT and shown as mean ± SEM. *P < 0.01 vs. NT, n=4, t-test.

**Protein profile of NADPH oxidase isoforms in Human RPT cells**

Except for Nox3 and Duox2, the five other NOX isoforms are ubiquitously expressed in tissues and organs of humans. NOX1, NOX2, and NOX4 proteins, which are present in RPT cells from humans [8] and rats, are expressed to a greater extent in SHRs than WKY rats [41,39,40]. We, therefore, determined whether or not NADPH oxidase isoform protein expression is also greater in RPT cells from hypertensive than normotensive humans (i.e., HT vs. NT). In agreement with the mRNA data, total cellular NOX2 and NOX4 proteins were similar in NT and HT (Fig. 2A and B), while total cellular NOX1 protein was slightly greater in HT (1.2 ± 0.1-fold) than NT (P=0.016) (Fig. 2A and B). By contrast, total cellular NOX5 protein was markedly greater in HT (5.2 ± 0.7-fold) than NT (Fig. 2A and B). Similar results were obtained using four other RPT cell lines from HT (n=2) and NT (n=2) (Fig. 5, supplementary file). NOX3 protein was not found in human RPT cells, in agreement with a previous report [13]. We also studied the effect of the number of cell passages on NOX5 mRNA expression, NOX5 protein, and ROS production (6 vs. 20 passages). NOX5 expression and ROS production were not different after 6 or 20 passages of HT cells (Fig. S3 supplementary file). In addition, 3 pairs of human RPT primary cells (4–10 passages) were studied for NOX5 protein expression and activity. In these lower passaged RPT cells, NOX5
NT and hypertensive subjects (HT). Human RPT cells were lysed in 2% SDS buffer and protein was also greater in HT than NT (Fig. S4A, supplementary file). (A). Immunoblotting (Santa Cruz) was determined by immunizing peptide blocking study (Fig. S2A, oxidase isoforms, as indicated. The specific isoform proteins Apical and basolateral membrane localization of NADPH oxidase (Fig. 3A, upper panel). In contrast, in RPT cells from HT, NOX5 was perinuclear area and to a lesser extent at the cell membrane (Fig. 3B). The presence of NOX5 protein at the RPT cell membrane (SOD) which dismutates superoxide to hydrogen peroxide abrogated by pretreatment of the HT cells with the NADPH oxidase activity to a greater extent in RPT cells from NT (−32.5 ±1.8%) than HT (−14.8 ± 1.8%) (P<0.01, t-test) (Fig. 4B). The effect of fenoldopam was specific to the D1-like receptor antagonist because the inhibitory effect of fenoldopam on NADPH oxidase activity was reversed by the addition of the other NOX isoforms in HT, relative to NT.

**NADPH oxidase activity and ROS production**

We used four different methods to measure NADPH oxidase activity and/or ROS production in RPT cells. First, total NADPH oxidase activity was measured in the presence of lucigenin and NADPH using whole cell membranes (Fig. 4A), as reported previously [8,31]. We have previously reported that basal NADPH oxidase activity was greater in RPT cells from SHRs than from WKY rats [31]. In the current study, basal total NADPH oxidase activity was also greater in RPT cells from HT (4.5 ±0.2-fold) than NT (Fig. 4A). In contrast, the D1-like receptor agonist fenoldopam, using a concentration that is less than the Vmax [29], decreased NADPH oxidase activity to a greater extent in RPT cells from NT (−32.5 ±1.8%) than HT (−14.8 ± 1.8%) (P<0.01, t-test) (Fig. 4B). The effect of fenoldopam was specific to the D1-like receptor antagonist Sch23390 in both NT and HT (Fig. 4B).

Calcium-dependent NADPH oxidase activity in total cell membranes was measured in the presence of 1.0 mmol/L CaCl₂ since NOX5 is a calcium-dependent enzyme [9,14,18,19,23]. NADPH oxidase activity expressed % control (no ionomycin) or RLUs is shown in Fig. S7A and B in the supplementary file. As shown in Fig. 4C, Left figure, calcium-independent NADPH oxidase activity was 2.3 ±0.3-fold greater in HT (230 ± 33%) than NT cells (100 ±16%) (P=0.003). However, calcium-dependent NADPH oxidase activity was even greater (3.6 ±0.7-fold) in HT (362 ±35%) than NT (100 ±76%) (P=0.001) (Fig. 4C, right figure).

NOX5 is a calcium-dependent enzyme and ionomycin, which raises the intracellular level of Ca²⁺, stimulates NOX5 activity [9,14,18,19]. Therefore, we studied the effect of ionomycin on NOX5 activity using whole cell membranes from HT cells only because NOX5 protein expression was minimally expressed in NT cells (Figs 1 and 2). Ionomycin stimulated NADPH oxidase activity only in the presence of calcium (Fig. S7A, supplementary file) [18]. Ionomycin increased membrane NADPH oxidase activity (+127.3 ±6.0% vs. 100.6 ±1.8%, vehicle control) (P=0.008, vs. control, ANOVA) (Fig. 4D). The stimulatory effect of ionomycin on NADPH oxidase activity was decreased below control values by SOD, or DPI.

Second, NOX5-specific oxidative activity was measured in immunoprecipitated NOX5 in the presence of CaCl₂. In HT and NT cells (4–18 passages) NOX5 activity in NOX5 immunoprecipitates was 2791.9 ±200.7 RLU in HT vs. 432.3 ±128.5 RLU in NT (P<0.003, Table S2, supplementary file). Fig. 5A, left figure, shows that basal NOX5 activity (measured immediately after the injection of NADPH, in the presence of calcium) was 6.2-fold greater in HT (624 ±25% of NT) than NT (100 ±4%) (P<0.001, t-test, n=6–14). The amount of NOX5 pulled down (Fig. S8 supplementary file) was also greater in HT (244 ±5%) than NT (102 ±2%) (P<0.03). Fig. 5A, right figure shows the NOX5 activity monitored over a period of 30 min. Following the injection of NADPH, NOX5 activity increased with the time, peaked at 10 min and started to decline at 15 min. Fig. 5B shows that in HT cells, ionomycin increased NOX5 activity by 25 ±6.3% compared with control (vehicle-treatment) (P<0.01 vs. control, one-way ANOVA). The effect of ionomycin on NOX5 activity was abrogated by pre-treatment of HT cells with either DPI or SOD, both of which decreased NOX5 activity below control values, similar to those observed for total NADPH oxidase activity (Fig. 4D).

Third, extracellular ROS production was measured by SOD-inhibitable reduction of cytochrome c in live RPT cells [19–21,37,38],
To evaluate the relationship between the localization of the NOX isoforms at the apical membranes and extracellular ROS production, we measured extracellular ROS production using the SOD-inhibitable reduction of cytochrome c. We found that extracellular ROS production was 2.6-fold greater in HT (45.9 ± 2.0 nmol/5 × 10⁶ cells) than NT (18.4 ± 3.5 nmol/5 × 10⁶ cells) (Fig. 5C) (P < 0.001, one-way ANOVA, Newman–Keuls test, n = 5/group). D₁-like receptor function, assessed by production of cAMP or inhibition of sodium transporter or pump activity, is impaired in kidney tissues and cells from humans with essential hypertension and SHRs.
Fig. 4. Measurement of NADPH oxidase activity in human RPT cells. (A). Measurement of NADPH oxidase activity in whole cell membranes of human RPT cells. Whole cell membranes were prepared as described under “Section 2”. NADPH oxidase activity was measured using a microplate luminometer as described under “Section 2”. NADPH oxidase activity was expressed as % of control (Con). Values are mean ± SEM of 4–7 separate experiments per group. *P<0.001, vs. NT, t-test. (B). Summary of NADPH oxidase activity from the studies shown in Fig. 4A. NADPH oxidase activity was calculated and converted to % of control (Con). Values are mean ± SEM of 4–7 separate experiments per group. #P<0.001, vs. others, #P<0.05 vs. Fen-HT, one-way ANOVA, Newman–Keuls test. (C). Measurement of calcium-independent and calcium-dependent NADPH oxidase activity in RPT cells. Whole cell membranes were prepared as described under “Section 2”. NADPH oxidase activity was measured in the absence or presence of CaCl2 (1.0 mmol/L). The calcium-independent (left figure) and -dependent (right figure) NADPH oxidase activities were expressed as RLU/50 μg protein (Fig. 5B) and expressed as % of NT (Fig. 4C; Values are mean ± SEM (n=8–12/group), *P=0.003 for left panel, and *P=0.001 for right panel, vs. NT, t-test. (D). Effect of ionomycin on NADPH oxidase activity in RPT cells from HT. RPT cells from HT were pre-treated with vehicle (VEH), superoxide dismutase (SOD, 400 units/ml), or diphenyleneiodonium (DPI, 30 μmol/L) for 45 min. The cells were then treated with vehicle (VEH, control [Con]) or ionomycin (ION, 1 μmol/L) (VEH + ION, SOD + ION, DPI + ION) for an additional 15 min in the presence of 0.65 mmol/L CaCl2 (equivalent to 47 μmol/L of free Ca2+) (18). The cell pellets were collected and whole cell membranes were prepared as in Fig. 4A. NADPH oxidase activity was measured using a microplate luminometer as described under “Section 2”. NADPH oxidase activity was expressed as % of control and shown as mean ± SEM (n=4/group). *P=0.008, vs. all others, #P<0.001, vs. SOD + ION and DPI + ION, one-way ANOVA, Newman–Keuls test.

These previous reports were corroborated by the current studies in that the D1-like receptor agonist fenoldopam decreased ROS production to a greater extent in NT (−39.1 ± 5.8) than HT (−17.1 ± 2.6) (Fig. 5C), in agreement with its decreased ability to inhibit NADPH oxidase activity in HT (Fig. 4B).

Finally, we used a fluorescence kit to label live RPT cells and visualized ROS production by confocal microscopy. The fluorescence intensity, measured under the same microscope setting, was much stronger in RPT cells from HT than NT, indicating that basal ROS production was greater in HT than NT (Fig. 5D), corroborating the results using the other methods to measure ROS production (Figs. 4A, C, and 5C). The finding that NOX5 co-localized with ROS in RPT cells from HT (Fig. 3A and Fig. 5S) indicated that intracellular ROS abundance was related to NOX5 protein abundance.

Effect of knockdown of NOX5 expression on NADPH oxidase activity

To determine if the increased NOX5 activity in RPT cells from HT was causal of the increased ROS production, we measured NADPH oxidase activity following the silencing of NOX5, using NOX5-siRNA. Because NOX5 protein in NT cells was barely detectable (Fig. 3A, Figs. S2, S4 and S5), only RPT cells from HT were used in the silencing experiments. To determine whether or not loss of NOX5 expression altered cellular behavior, cell number was measured following the silencing of NOX5 with NOX5-siRNA in HT cells. Silencing NOX5 decreased NOX5 protein by 56 ± 9% (Fig. 6A) but did not alter cell number (Figs. 59A and B, supplementary file). In another set of studies, NOX5 protein expression was decreased by −40 ± 6.2% (data not shown) and NADPH oxidase activity was decreased by −45 ± 3.2% (Fig. 6B) in NOX5-siRNA treated HT RPT cells, relative to mock-siRNA-treated HT RPT cells. NOX5 activity was also measured with or without ionomycin following the silencing of NOX5 gene. Ionomycin increased NOX5 activity to a greater extent in mock-silenced (mock-siRNA) HT cells (+31.3 ± 2.8%) than in NOX5-silenced (NOX5-siRNA) HT cells (+14.6 ± 3.2%) (P<0.02, ANOVA) (n=6) (Fig. 6C); SOD or DPI decreased NADPH oxidase activity in both mock-siRNA and NOX5-siRNA-treated RPT cells, to levels below control values, similar to HT cells not treated with NOX5-siRNA (Fig. 5B).
**Fig. 5.** Measurement of NOX5 activity and extracellular ROS production in RPT cells. (A). Measurement of NOX5 activity in RPT cells. Left figure shows basal NOX5 activity in NOX5 immunoprecipitates of RPT cells from normotensive (NT) and hypertensive subjects (HT). Human RPT cells were lysed as described under “Section 2”. The cell lysates were immunoprecipitated with polyclonal anti-NOX5 antibody. NOX5-dependent oxidase activity was measured by incubating the NOX5-immunoprecipitates with assay buffer in the presence of CaCl2 (1.0 mmol/L), lucigenin (50 μmol/L) and NADPH (200 μmol/L) using a microplate luminometer, as described under “Section 2.” The first readings, which were obtained immediately following the injection of NADPH (final concentration = 200 μmol/L), represented basal NOX5 activity (left figure). NOX5 activity was calculated and expressed as RLU and converted to % of NT. Values are mean ± SEM of 6–14/group, nP = 0.001, vs. NT, t-test. Right figure shows the NOX5 activity monitored for a period of 30 min following the injection of NADPH, in the presence of calcium. Values are mean ± SEM of 6–14/group, nP = 0.001, vs. NT, #P = 0.001, vs. all other time points, one way ANOVA, Newman–Keuls test. (B). Effect of ionomycin on NOX5 activity in HT cells. Cells were pre-treated with vehicle (VEH), ION (ionomycin), SOD (superoxide dismutase), or DPI (diphenyleneiodonium) as described in Fig. 4D. The cell lysates were subjected to immunoprecipitation and NOX5 activity was measured as in Fig. 5A. Values are mean ± SEM of 4/group, *P < 0.01, vs. other groups, #P < 0.001, vs. SOD + ION and DPI + ION, one-way ANOVA, Newman–Keuls test. (C). Measurement of extracellular ROS production in RPT cells. Extracellular ROS production was measured by SOD-inhibitable reduction of cytochrome c in live RPT cells. Cells, cultured on 12-well plates (5 x 10⁶/well), were incubated in 0.5 ml phenol-free DMEM/F12 medium containing reduced cytochrome c (200 μmol/L) with or without SOD (200 μmol/L) for 15 min at 37 °C. The incubation was continued for another 30 min in the presence of vehicle (control, Con) or fenoldopam (Fen, 1 μmol/L). The absorbance of reduced cytochrome c was measured at 550 nm, and SOD-inhibitable reduction of cytochrome c was calculated (37). The upper figure shows ROS production expressed as nmol/5 x 10⁶ cells and the lower figure shows values expressed as % of Con. Values are mean ± SEM of 5/group. Upper panel: *P < 0.05, vs. Con (NT or HT), *P < 0.01, vs. NT Con, *P < 0.01, vs. NT Fen, n = 5, one-way ANOVA, Newman–Keuls test. Lower panel: *P < 0.01, vs. Con (NT or HT), *P < 0.05, vs. NT-Fen, n = 5, one-way ANOVA, Newman–Keuls test. (D). Visualization of ROS in live cells. ROS were labeled in live cells with CellROS Deep Red fluorogenic probe and visualized by confocal microscopy. Cells, grown on coverslips, were incubated in phenol-free DMEM/F12, containing 1% dialyzed FBS with fluorogenic probe at a final concentration 5 μmol/L for 30 min at 37 °C. The coverslips were washed, fixed, and mounted as described under “Section 2.” NT cells served as control for HT cells. ROS (triplicate: 1, 2, 3) were detected by confocal microscopy (excitation and emission wave lengths at 640 and 655 nm, respectively) at 630 × magnification.
Discussion

The role of NOX isoforms in physiological and pathological states is well documented. However, studies of NOX5 are relatively rare because this gene is not found in rodents [12,13]. By contrast, the NOX5 gene is present in humans and its protein is expressed in fetal [13] and non-fetal organs and tissues, including the lung, testis, spleen [14], and vascular endothelial, smooth muscle [3,7,9,10,15–17,41], and gastrointestinal [42] cells. We now show for the first time that NOX5 mRNA and protein are expressed in human RPT cells.

NADPH oxidase enzymes are the major sources of ROS production in renal and cardiovascular tissues [2,4–9]. The increased generation of ROS contributes to human [10,11] and animal hypertension [2,4,5,10,29–32,43]. NADPH oxidase activity and superoxide formation are increased in endothelial [2,10,41,43], neural [5,43], renal [2,29–32,43,44], and vascular smooth muscle cells [4,28,41,43] in genetic and acquired hypertension. Of the NOX isoforms that are present in rodents (Nox1, Nox2, and Nox4) [2,7–9,29–32,39], Nox4 has been claimed to be the major NADPH oxidase in renal [6,43], vascular smooth muscle [4,7,41,43], and endothelial cells [41,43], and its expression is markedly increased in hypertensive rodents [2,31,35,43]. It has also been reported that injection of siRNA against-NOX2 or NOX4 into the hypothalamic paraventricular nucleus attenuates the development of aldosterone/salt-induced hypertension [5]. Therefore, Nox4 may play vital role in the pathogenesis of animal hypertension. By contrast, human microvascular endothelial cells possess functionally active NOX5 which generates ROS and is regulated by angiotensin II and endothelin 1 [14–16,41]. In patients with coronary artery disease, NOX5 protein and mRNA levels and NADPH oxidase-dependent production of ROS in coronary arterial membranes are increased [9]. We now report for the first time that NADPH oxidase activity and mRNA and total cellular protein expressions of NOX5 and NOX1, but not NOX2 and NOX4 are increased in RPT cells from HT relative to NT. We also report that the apical membrane expressions of NOX1, NOX2, NOX4, and NOX5 are increased in RPT cells from HT relative to NT. However, the increase in NOX5 expression in HT is greater than the other NOX isoforms. Moreover, the increase in NOX5 expression and activity in HT is associated with increased production of ROS. Therefore, we speculate that increased NOX5 expression may be important in the pathogenesis of human essential hypertension.

The increase in NOX proteins, especially NOX5 at the apical and plasma membranes in RPT cells from HT, is associated with increased extracellular ROS production. This may be related to polybasic domains within the N-terminus of NOX5, that can bind phosphatidylinositol 4,5- bisphosphate at the plasma membrane,
and promote the trafficking and cell surface expression of NOX5 [20,21]. NOX5 in the endoplasmic reticulum and nucleus may also contribute to intracellular ROS production [20,21,23]. The colocalization of NOX5 with ROS in RPT cells from HT could be taken to indicate that the increased intracellular ROS in HT is related to NOX5 protein abundance.

NOX5 protein is expressed predominantly in the plasma membrane and to a lesser extent in the cytosol and nucleus. NOX1-5 proteins have been reported to be expressed in many subcellular areas, including the nucleus in human endocardial and vascular endothelium, vascular smooth muscle, esophageal adenocarcinoma, prostate cancer, and leukemia cells [18,41,42,44,45]. In agreement with these reports, confocal imaging shows that NOX5 protein and ROS colocalize in the plasma membrane and nucleus of RPT cells from HT. Therefore, nuclear NOX5-dependent ROS production may also contribute to total cellular oxidative stress. Whether or not nuclear NOX5 is involved in redox responsive gene expression remains to be determined [44].

Ionomycin, an ionophore that increases intracellular Ca$^{2+}$ and NADPH oxidase activity [14,18,19], also stimulates NOX5 activity in HT cells. The stimulatory effect of ionomycin on ROS production is abrogated by DPI, an NADPH oxidase inhibitor, and SOD which catalyzes the dismutation of superoxide to H$_2$O$_2$. These data support the notion that activation of NOX5 is responsible for the increase in ROS production, specifically superoxide. There are at least five splice variants of NOX5 (α, β, δ, γ, and ε) [15,23]. Ionomycin stimulates NOX5α and β but not the other NOX5 isoforms to produce superoxide [23]. It remains to be determined whether these NOX5 isoforms are responsible for the increased ROS production in RPT cells from HT or NOX5 polymorphisms, if they exist, are associated with the hypertensive phenotype. Nevertheless, increased NOX5 expression and activity are likely to be important in the increased ROS production in RPT cells from HT because silencing of NOX5 with siRNA decreases basal NADPH oxidase activity in RPT cells from HT.

In conclusion, we report for the first time that NOX5 is negatively regulated by D$_1$-like receptors in RPT cells from humans [8] and RPT and vascular smooth muscle cells from rats [28–32]. The inhibitory effect of fenoldopam, a D$_1$-like receptor agonist, on NADPH oxidase activity is probably exerted at the D$_1$-like receptor because a D$_1$-like receptor antagonist, Sch23390, blocks the fenoldopam effect. The decreased ability of fenoldopam to inhibit NADPH oxidase activity in HT relative to NT is in agreement with our previous report that fenoldopam inhibits NADPH oxidase activity to a lesser extent in RPT cells from SHRs than those from normotensive WKY rats [31]. A defective D$_1$-like receptor may have caused the impaired ability of fenoldopam to inhibit NADPH oxidase activity in the RPT cells from HT. We and others have reported a decreased ability of D$_1$-like receptors to inhibit RPT sodium reabsorption [27], and stimulate cAMP production and inhibit sodium transport in RPT cells from hypertensive humans [33], three animal models of hypertension [11,24,32], and obese hypertensive rats [46]. The impairment in renal proximal tubular D$_1$-like receptor function in hypertension is caused by constitutive phosphorylation of D$_1$R, as a consequence of increased activity of type 2 and type 4 G protein-coupled receptor kinases [24,33,46,47].

In conclusion, we report for the first time that NOX5 is the predominant NOX isoform expressed in human RPT cells and its expression and activity in RPT cells are increased in humans with essential hypertension. Although the latter conclusion is limited by the small number of subjects (three normotensive and three hypertensive subjects), NOX5 expression in RPT cells was always greater in HT than in NT. Thus, it is likely that increased NOX5 expression and activity may be responsible for the oxidative stress that contributes to the pathogenesis of human essential hypertension.
membrane and generates superoxide in response to protein kinase C activation, Biochimie 89 (2007) 1159–1167.

[22] F. Tirone, L. Radu, C.T. Craescu, J.A. Cox, Identification of the binding site for the regulatory calcium-binding domain in the catalytic domain of NOX5, Biochemistry 49 (2010) 761–771.

[23] D. Pandey, A. Patel, V. Patel, F. Chen, J. Qian, Y. Wang, S.A. Barman, R.C. Venema, D.W. Stepp, R.D. Rudic, D.J. Fulton, Expression and functional significance of NADPH oxidase 5 (Nox5) and its splice variants in human blood vessels, Am. J. Physiol. Heart Circ. Physiol. 302 (2012) H1919–H1928.

[24] C. Zeng, I. Armando, Y. Luo, G.M. Eisner, R.A. Felder, P.A. Jose, Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice, Am. J. Physiol. Heart Circ. Physiol. 29 (2008) H551–H560.

[25] T. Hussain, M.F. Lokhandwala, Renal dopamine receptors and hypertension, Exp. Biol. Med. (Maywood) 228 (2003) 134–142.

[26] I. Saito, S. Itaui, E. Takeshita, H. Kawabe, M. Nishino, H. Winai, C. Hasegawa, T. Saruta, S. Nagan, T. Sekihara, Increased urinary dopamine excretion in young patients with essential hypertension, Clin. Exp. Hypertens. 6 (1994) 29–39.

[27] D.P. O’Connell, N.V. Ragsdale, D.G. Boyd, R.A. Felder, R.M. Carey, Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status, Hypertension 29 (1997) 115–122.

[28] K. Yasunari, M. Kohno, H. Kano, M. Minami, J. Yoshikawa, Dopamine as a novel antioxidative agent for rat vascular smooth muscle cells through dopamine D1-like receptors, Circulation 101 (2000) 2302–2308.

[29] Z. Yang, L.D. Asico, P. Yu, Z. Wang, J.E. Jones, C.S. Fraga, P.A. Jose, P. Andrews, G.,M. Eisner, U. Hopfer, R.A. Felder, D1 dopamine receptor hyperphosphorylation in renal proximal tubule cells, Hypertension 53 (2009) 1054–1061.

[30] H. Li, W.X. Han, Y.V. Mukhin, M.N. Garnovskaya, G. Collinsworth, J. Zhang, J.R. Raymond, 5-Hydroxytryptamine 1A receptor/Gi/o stimulates mitogen-activated protein kinase via NAD(P)/H oxidase and reactive oxygen species upstream of Src in Chinese hamster ovary fibroblasts, Biochem. J. 347 (2000) 61–67.

[31] S. Simão, S. Fraga, P.A. Jose, P. Soares-da-Silva, Oxidative stress plays a permissive role in a2-adrenoceptor-mediated events in immortalized SHR proximal tubular epithelial cells, Mol. Cell Biochem. 315 (2008) 31–39.

[32] R. Pedrosa, V.A. Villar, A.M. Pascua, S. Simão, U. Hopfer, P.A. Jose, P. Soares-da-Silva, Increased NADPH oxidase activity and Nox4 expression in human renal tubular epithelial cells, Br. J. Pharmacol. 153 (2008) 1445–1455.

[33] T.M. Paracivcini, S. Chissobolias, G.R. Drummond, C.G. Sohey, Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo, Stroke 35 (2004) 584–589.

[34] J. Gilded, I. Shah, R. Weiss, N.D. Casscells, E.H. McGrath, J. Zhang, R.A. Felder, HK-2 human renal proximal tubule cells as a model for G protein-coupled receptor kinase type 4-mediated dopamine 1 receptor uncoupling, Hypertension 56 (2010) 505–511.

[35] E. Pick, D. Mizio, Rapid microarrays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader, J. Immunol. Methods 46 (1981) 211–226.

[36] Y.V. Mukhim, M.N. Garnovskaya, C. Collinsworth, J.S. Grewal, D. Pendergrass, T. Nagaj, S. Pinckney, E.L. Greene, J.R. Raymond, 5-Hydroxytryptamine 1A receptor/Gi/o stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of Src in Chinese hamster ovary fibroblasts, Biochem. J. 347 (2000) 61–67.

[37] E. Pick, D. Mizio, Rapid microarrays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader, J. Immunol. Methods 46 (1981) 211–226.

[38] R. Pedrosa, V.A. Villar, A.M. Pascua, S. Simao, U. Hopfer, P.A. Jose, P. Soares-da-Silva, Oxidative stress plays a permissive role in a2-adrenoceptor-mediated events in immortalized SHR proximal tubular epithelial cells, Mol. Cell Biochem. 315 (2008) 31–39.

[39] R. Pedrosa, V.A. Villar, A.M. Pascua, S. Simão, U. Hopfer, P.A. Jose, P. Soares-da-Silva, H2O2 stimulation of the Cl–/HCO3– exchanger by angiotensin II and angiotensin II type 1 receptor distribution in membrane microdomains, Hypertension 51 (2008) 1332–1338.

[40] L. Abmarcini, L. Avedanian, J. Al-Khoury, C. Berreault, D. Jacques, G. Bkaily, Whole-cell and nuclear NADPH oxidases levels and distribution in human endocardial endothelial, vascular smooth muscle, and vascular endothelial cells, Can J. Physiol. Pharmacol. 91 (2013) 71–79.

[41] X. Fu, D.G. Beer, J. Behar, J. Wands, D. Lambert, W. Cao, cAMP-response element-binding protein mediates acid induced NADPH oxidase NOX5 expression in Barrett esophageal adenocarcinoma cells, J. Biol. Chem. 281 (2006) 20368–20382.

[42] R. Lassègue, K.K. Griendling, Reactive oxygen species in hypertension, Am. J. Hypertens. 17 (2004) 852–860.

[43] M. Ushio-Fukai, Localizing NADPH oxidase-derived ROS, Sci. STKE 349 (2006) pe8.

[44] S.S. Brar, Z. Corbin, T.P. Kennedy, R. Hemendinger, L. Thornton, B. Bommarius, R.S. Arnold, A.R. Whorton, A.B. Sturrock, T.F. Huecksteadt, M.T. Quinn, K. Krenitsky, K.G. Ardie, J.D. Lambeth, J.R. Hoidal, NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells, Am. J. Physiol. Cell Physiol. 285 (2003) C353–C369.

[45] M. Trivedi, M.F. Lokhandwala, Rosiglitazone restores renal D1A receptor-Gi/o protein coupling by reducing receptor hyperphosphorylation in obese rats, Am. J. Physiol. Renal. Physiol. 289 (2005) F298–304.

[46] P. Yu, L.D. Asico, Y. Luo, P. Andrews, G.M. Eisner, U. Hopfer, R.A. Felder, P.A. Jose, D1 dopamine receptor hyperphosphorylation in renal proximal tubules in hypertension, Kidney. Int. 70 (2006) 1072–1079.